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Summary
Background: Cell-to-cell variability in populations has been
widely observed in mammalian cells. This heterogeneity can
result from random stochastic events or can be deliberately
maintained through regulatory processes. In the latter case,
heterogeneity should confer a selective advantage that bene-
fits the entire population.
Results: Using multicolor flow cytometry, we have uncovered
robust heterogeneity in phosphoinositide 3-kinase (PI3K)
activity in MCF10A cell populations, which had been previ-
ously masked by techniques that only measure population
averages. We show that AKT activity is bimodal in response
to EGF stimulation and correlates with PI3K protein level,
such that only cells with high PI3K protein can activate AKT.
We further show that heterogeneity in PI3K protein levels is
invariably maintained in cell populations through a degrada-
tion/resynthesis cycle that can be regulated by cell density.
Conclusions: Given that the PI3K pathway is one of the most
frequently upregulated pathways in cancer, we propose that
heterogeneity in PI3K activity is beneficial to normal tissues
by restricting PI3K activation to only a subset of cells. This
may serve to protect the population as a whole from over-
activating the pathway, which can lead to cellular senescence
or cancer. Consistent with this, we show that oncogenic muta-
tions in p110a (H1047R and E545K) partially evade this nega-
tive regulation, resulting in increased AKT activity in the
population.
Introduction
Among the thousands of proteins expressed in a single cell at
any one time, it is inevitable that even genetically identical cells
will have variable expression of certain proteins. This cell-to-
cell heterogeneity can have profound effects on the phenotype
of a population. In bacteria and yeast, a heterogeneous
population has a better chance of surviving in fluctuating envi-
ronments [1–3]. In cancer cells, variable protein expression
results in nonuniform responses to anticancer agents and
only ‘‘fractional’’ killing, which is beneficial to the tumor but
detrimental to the patient [4–7].
Population heterogeneity can be the result of genetic and
nongenetic variability [8]. Nongenetic sources of heterogeneity*Correspondence: lewis_cantley@hms.harvard.edu
5Present address: Helen Diller Family Comprehensive Cancer Center,
University of California, San Francisco, San Francisco, CA 94158, USAare of particular interest because they are not fixed in the
population by heritable transmission. Rather, these sources
can be stochastic in nature, such as random fluctuations in
transcription or translation, or they can be regulated, such as
through feedback mechanisms, so that variability is deliber-
ately maintained. Flow cytometry allows us tomeasure protein
concentrations in single cells within large populations, which
has proved useful in differentiating between stochastic and
regulated sources of variation. Variable protein levels caused
by stochastic events are usually rare and slightly increase
the coefficient of variance of an otherwise log-normal concen-
tration distribution [9]. Regulated variance usually deviates
from tight log-normal distributions and in the most extreme
cases might display bimodality [10]. Additionally, variance in
the expression level of these proteins tends to correlate with
variance in functionally related proteins [9].
We demonstrate cell-to-cell variability in phosphoinositide
3-kinase (PI3K) pathway activation in mammary epithelial cells
that is indeed bimodal and also correlates with multiple
proteins in the pathway. This implies that heterogeneous
PI3K activation in cell populations ismaintained by a regulated
process and likely confers a selective advantage. The PI3K
pathway regulates numerous critical cellular functions such
as proliferation, growth, and survival and is one of the most
frequently altered pathways in human cancer [11]. Tumor cells
have evolved numerousways of overactivating this pathway to
induce tumorigenesis, such as amplifications or mutations in
upstream receptor tyrosine kinases (RTK), mutations or
deletion of the negative regulator PTEN, somatic mutations
in PI3K itself, and combinations of the above [12–14]. In this
view, we propose that cell-to-cell variability in PI3K activity
serves as a mechanism to keep overall PI3K activity limited
in normal tissues to avoid hyperactivity that may lead to
cancer.
Results
AKT Activation in MCF10A Populations Is Heterogeneous
and Exhibits a Bimodal Distribution
To assess cell-to-cell variability in PI3K pathway activation, we
acutely stimulated serum- and growth factor-starved MCF10A
cells with EGF and measured AKT activity in single cells by
flow cytometry. As expected, in the absence of EGF or with
pretreatment with the PI3K inhibitor wortmannin, cells ex-
hibited a log-normal distribution in the pAKT-negative gate
(Figure 1A). Following treatment with saturating amounts of
EGF, we observed striking heterogeneity in AKT activation
characterized by the bimodal distribution of cells into the
pAKT-negative (w70%) or pAKT-positive (w30%) gates
(Figure 1A). The percentage of cells in the positive gate was
maximal at 5–10 min and decreased over time. We found
that the bimodality was not due to differential EGFR activation
or total AKT protein abundance, both of which exhibit
log-normal distributions and show weak correlation with
pAKT status (see Figures S1A and S1B available online). Bimo-
dality was also observed following insulin stimulation, sug-
gesting that this is a general, rather than ligand-specific, effect
on PI3K activation (Figure S1C). We also observed robust
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Figure 1. PI3K Pathway Activation in MCF10A
Populations Is Heterogeneous
(A) Cells were starved and acutely stimulated
with 5 nM EGF for 5 min with or without pretreat-
ment with 100 nM wortmannin. Cells were then
harvested and stained with anti-pAKT S473 anti-
body and analyzed by flow cytometry. Unstimu-
lated and wortmannin-treated cells are pAKT
negative (P6). EGF stimulation activates w30%
of cells and shifts them into the pAKT-positive
gate (P7). Cells stably expressing the oncogenic
H1047R p110amutant exhibit basal AKT activity
in the unstimulated state (as previously
reported), and EGF stimulation shifts more cells
into the pAKT-positive gate (P7) and also
increases the amplitude of pAKT signal (P8).
(B) Mammary carcinomas from MMTV-Cre;
BRCA1flox/flox; p53+/2 mice display heteroge-
neous pAKT positivity.
(C) MCF10A cells stably expressing HA-tagged
p110a were treated as described in (A) and cos-
tained with anti-pAKT S473 and anti-HA anti-
bodies. HA-p110a segregates into a bimodal
distribution and correlates with pAKT status
(R2 = 0.68).
(D) The results from (C) were validated by immu-
nofluorescence.
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174bimodal activation of AKT in another nontransformed human
mammary epithelial cell line (HMEC; Figure S1E).
As reported in the literature, cell populations expressing the
oncogenic H1047R PIK3CAmutation have higher AKT activity
[15–17]. The enzyme encoded by this mutant form of PIK3CA
has been shown to have higher specific activity than that
encoded by wild-type PIK3CA [15, 16]. To explore the possi-
bility that this mutation shifts cells uniformly to the pAKT-posi-
tive state, we analyzed MCF10A cells stably expressing this
mutant form of p110a by flow cytometry. We observed that
even in the presence of oncogenic p110a, cells still segregate
into a bimodal distribution and retain a substantial population
of nonresponders. The H1047Rmutation in MCF10A cells thus
achieves higher average pAKT levels by shiftingmore cells into
the pAKT-positive state (Figure 1A). This implies that the
mechanism that maintains heterogeneity in cell populations
is both robust and not eliminated by expression of a mutant
form of PI3K with constitutively high specific activity.
Finally, we wanted to ensure that heterogeneous AKT
activation is preserved in more physiological settings. Debnath
et al. have previously observed sporadic pAKT staining in
MCF10A 3D acinar structures, which is important for proper
lumen formation [18, 19]. To see whether this heterogeneous
AKTactivationwasobserved invivo,weanalyzedspontaneously
arising tumors from MMTV-Cre; BRCA1flox/flox; p53+/2mice and
indeed observed heterogeneity in pAKT positivity (Figure 1B).p110a Protein Level Is Variable
in Single Cells and Determines
AKT Activity
Given that the bimodal AKT activation
could not be explained by bimodal
distribution of activated EGFR or total
AKT protein, we next looked for vari-
ability in PI3K protein abundance. There
are no p110a antibodies amenable for
flow cytometry, but pAKT bimodality
was maintained in MCF10A cells stablyexpressing HA-tagged p110a. We thus utilized anti-HA
antibodies to monitor levels of p110a. Using single-cell anal-
ysis, we found that p110a protein levels, like pAKT, exhibit
bimodality in cell populations (Figure 1C). p110a protein level
also positively correlated with pAKT status (R2 = 0.68),
indicating that only cells with high levels of p110a can activate
AKT. Cells with medium levels of p110a have intermediate
levels of AKT activity, suggesting that these cells may be tran-
sitioning dynamically between the two dominant modes
(Figure 1C). Subpopulations in these varying states can also
be visualized by immunofluorescence (Figure 1D).
The p85a-p110a heterodimer is a very stable complex that
does not readily dissociate, and it is thus thought that p110a
levels generally correlate with p85a levels [20, 21]. We moni-
tored the distribution of endogenous p85a in MCF10A cells,
and we show that levels of endogenous p85a mirror that of
HA-tagged p110a in single cells (Figure S1D). This correlation
indicates that the heterogeneity we observe is not an artifact of
exogenously expressed p110a and confirms that high levels of
the entire functional holoenzyme are required for AKT activa-
tion, as expected.
p110a Protein Levels Are Dynamic within Single Cells
In agreement with previous studies [22–24], total PI3K levels
do not appear to change upon growth factor stimulation, as
measured by western blot (Figure 2A). To test the possibility
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Figure 2. p110a Levels Are Dynamic within Single Cells
(A) MCF10A cells stably expressing wild-type HA-p110a were starved and acutely stimulated with 5 nM EGF. Cell lysates were harvested at indicated time
points and analyzed by SDS-PAGE.
(B) MCF10A cells stably expressing wild-type HA-p110awere treated as described in (A). Cells were harvested at indicated time points and analyzed by flow
cytometry. The average p110a level in the population (solid blue line) remains low and unchanging, as seen bywestern blot in (A). On the subpopulation level,
pAKT-positive cells (solid red line) initially have high levels of p110a, which drop precipitously at 10 min and recover over time. The pAKT-negative subpop-
ulation (dotted red line) retains constant low levels of p110a. The dynamic changes in p110a levels in the pAKT-positive subpopulation can modestly influ-
ence p110a levels of the entire population, as seen by the slight increase in p110a in the presence of MG132 (dotted blue line).
(C) The proportion of cells in the p110ahigh/medium/low gates was measured at each time point in a representative experiment described in (B). Fold change
compared to time 0 is shown, indicating a shift of cells from the p110ahigh to p110amedium to p110alow states and back. The short 4 hr time course ensures that
these dynamic changes are not due to cell division.
(D) Average AKT activity was measured on the population and subpopulation levels in the cells from (B). p110ahigh cells (solid black line) maximally activate
AKT compared to p110alow cells (dashed black line), which minimally activate AKT. p110amedium cells (dotted black line) have intermediate levels of pAKT.
Given that the p110ahigh cells only representw30% of the population, the average pAKT level on the population level (red line) is only slightly higher than the
p110alow line. Data are from at least three independent experiments, and error bars represent standard error of the mean.
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175that p110a protein levels are dynamic on the subpopulation
level, we measured p110a levels in pAKT-positive and pAKT-
negative subpopulations over a time course of EGF stimulation
by single-cell analysis. Surprisingly, we observed dynamic
changes in p110a protein in pAKT-positive cells. This minorsubgroup of cells has the highest levels of p110a (and the high-
est levels of pAKT) and undergoes a precipitous drop in p110a
protein at 10 min after EGF stimulation, when AKT activity is
maximal (Figure 2B). Over the next 4 hr, this population grad-
ually recovers p110a levels (Figure 2B). In contrast, the major
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176subgroup of cells with low levels of pAKT and low p110a does
not show a significant decline in p110a (or activation of AKT)
during the time course of EGF stimulation. We attempted to
verify these results with live cell imaging of fluorescently
tagged p110a, but the size of the fluorescent protein-p110
fusion prohibited efficient transfection and expression.
However, our observed changes in p110a levels also corre-
late with a striking change in the proportion of cells in the
p110ahigh, p110amedium, and p110alow subpopulations over
the time course of EGF stimulation. After 10 min of EGF stimu-
lation, there is a major drop in the proportion of cells in the
p110ahigh state and an increase in the proportion of cells in
the p110amedium state (Figure 2C). Over the next 4 hr, the
populations recover to the original distribution (Figure 2C).
These data indicate that there is a significant decrease in
p110a levels in a subpopulation of cells characterized by
high pAKT and high p110a. The failure to detect this acute
change in p110a by western blot can be explained by the
fact that this population represents only a minor fraction of
total cells, whereas the protein in a western blot is dominated
by a major fraction of cells (70%–80%) that fail to activate the
PI3K/AKT pathway and maintain static p110a levels. Endoge-
nous p85a levels exhibit nearly identical kinetics to p110a,
indicating that the entire holoenzyme is dynamically regulated
to modulate AKT activity (Figure S2).
We also plotted the time course of EGF-stimulated AKT
phosphorylation in the subpopulations of cells that had high,
medium, or low levels of p110a (Figure 2D). The subset of cells
with the highest level of p110a had not only the highest pAKT
signal amplitude but also the longest pAKT signal duration.
However, the overall population response was dominated by
the major subset of cells that had minimal AKT
phosphorylation.
Dynamic Changes in p110a Protein Levels Are Regulated
by a Degradation/Resynthesis Cycle
We next sought to understand themechanism by which p110a
levels were modulated. In these cells, HA-p110a expression is
driven by the CMV promoter, suggesting that variability in
p110a expression is posttranscriptionally regulated. To test
whether the drop in p110a levels in actively signaling cells
was due to proteosome-mediated degradation, we treated
cells with MG132 and observed an increase in p110a protein
on the population level (Figure 3A). On the subpopulation level,
MG132 treatment resulted in the accumulation of cells in the
p110amedium state and a loss of cells from the p110alow state
(Figure 3B). This suggests that proteosome-mediated degra-
dation of p110a transitions cells from the p110ahigh/medium
state to the p110alow state, thereby negatively regulating
AKT activity. Short-term treatment of cells with MG132 prior
to acute EGF stimulation partially rescues the drop in p110
levels in pAKT high cells and prevents the shift of cells from
the p110ahigh to p110amedium state (Figures S3A and S3B).
To show that p110a can be resynthesized and thus transition
cells from the p110alow to the p110amedium/high state, we
treated cells with cyclohexamide (CHX). On the population
level, we observed an overall decrease in p110a protein with
CHX treatment (Figure 3A). On the subpopulation level, we
observed an accumulation of cells in the p110alow state with
concomitant loss of cells from the p110amedium and p110ahigh
states (Figure 3B). These data show that p110a resynthesis
is responsible for shifting cells from the p110alow state to
the p110ahigh state, thereby generating cells competent to
activate AKT.Our results thus far suggest amodel whereby p110a levels in
single cells oscillate via a degradation/resynthesis cycle,
which transitions cells through phases of high p110a
(competent to activate the pathway) and low p110a (in-
competent to activate the pathway). Large populations
contain cells in various stages of this cycle, thus accounting
for the vast heterogeneity we observe (Figure 3C). Though
many extrinsic factors are likely to influence the duration and
progression of this cycle, we found no correlation between
p110a or pAKT status with cell cycle, as assessed by DNA
content, or with cell size or granularity (Table S1 and
Figure S3C).Hot Spot PIK3CA Mutations Confer Stabilization
of the p110ahigh State
Escaping this negative regulation of AKT may be particularly
important in cancer cells, given that H1047R-expressing
MCF10A cells and several tumor-derived breast cancer cell
lines can activate AKT in a greater proportion of cells
compared to nontransformed cell lines (Figure 1A; Figure S1E).
To test whether this was due to the ability to stabilize the
p110ahigh state, we measured the level of p110a in MCF10A
cells stably expressing exogenous HA-tagged wild-type,
H1047R mutant, or E545K mutant p110a.
Both mutant forms of p110awere expressed at higher levels
than wild-type p110a (Figure 4A), which was due to the
maintenance of more cells in the p110ahigh state and fewer
cells in the p110alow state (Figures 4B, 4C, and 4H). To ensure
that these differences were not due to variability in retroviral
infection efficiency, we tested multiple batches of cell lines,
and all lines were grown under selection for several genera-
tions before use in experiments.
We next sought to determine whether the mutant forms of
p110a were stabilizing the p110ahigh state by resisting degra-
dation. We monitored the degradation kinetics of the mutant
cell lines as we did in Figure 2B. Though both mutant cell lines
underwent rapid p110a degradation following EGF stimula-
tion, the E545K mutant displayed more muted degradation
(though this was, in part, due to higher basal expression),
and both mutants exhibited considerable variability between
experiments compared to wild-type (Figure 4D). Additionally,
MG132 treatment of asynchronously growing mutant cells
did not result in an increase in overall p110a levels, as
observed in the wild-type line (Figure 4E). These results
suggest that the H1047R and E545K mutations confer
resistance to proteosome-mediated degradation under expo-
nential growth conditions that may be distinct from the acute
degradation that occurs following EGF stimulation of starved
cells. Notably, all cell lines responded similarly upon CHX
treatment, ruling out the possibility that mutant p110a is
preferentially synthesized (Figure 4E).
To determine whether stabilization of PI3K contributes to
the oncogenic potential of the mutants, we compared overall
AKT activity to total p110a levels in mutant and wild-type cells.
During exponential growth, H1047R- and E545K-expressing
cells had 3.9-fold and 2.4-fold, respectively, more total AKT
activity than those expressing wild-type PIK3CA, though the
corresponding p110a levels were only 2.0-fold and 1.7-fold
higher (Figures 4A, 4F, and 4G). Given that these mutant forms
of p110a aremore enzymatically active [15, 16], we predict that
the combination of more cells in the p110ahigh state and higher
enzymatic activity cooperate to induce oncogenic levels of
AKT activity.
Figure 3. Changes in p110a Levels Are Regulated by a Degradation/Resynthesis Cycle
(A) Asynchronously growing MCF10A cells expressing wild-type HA-p110awere treated for 4 hr with 100 mg/mL cyclohexamide (CHX) or 20 mMMG132 and
analyzed by flow cytometry. Left: on the population level, CHX (blue line) and MG132 (orange line) treatment shifted the p110a distribution to the left and
right, respectively, compared to untreated cells (green line). Right: these shifts in p110a levels correlate with changes in overall pAKT level.
(B) On the subpopulation level, CHX treatment inhibits the accumulation of cells in the p110amedium/high gates by retaining cells in the p110alow state. MG132
treatment results in the accumulation of cells in the p110amedium/high gates. Changes in population distribution are quantified in the right panel. Data are from
at least three independent experiments, and error bars represent standard error of the mean.
(C)Model of PI3K degradation/resynthesis cycle that regulates pathway activation. Left: inactive cells are p110alow; pAKTlow (Q4). Extrinsic signals trigger de
novo synthesis of PI3K protein, transitioning cells to a p110ahigh; pAKTlow state (Q1), where they are competent to activate the pathway. Once a growth signal
is received, cells transition to the p110ahigh; pAKThigh state (Q2), and the PI3K pathway is fully activated. Shortly after activation, PI3K is rapidly degraded and
cells enter the p110alow; pAKThigh state (Q3). Once AKT is fully dephosphorylated, cells return to the inactive (Q4) state. Right: immunofluorescence of EGF-
stimulated cells shows cells in each of these four stages of the cycle.
Heterogeneous PI3K Activation in Cell Populations
177p110ahigh Cells Initiate Colony Formation
We next investigated whether p110ahigh cells had unique func-
tional roles. We seeded single cells from wild-type, H1047R,
and E545K parental cell lines and generated clonal cell lines.
Remarkably, nearly 100%of the clones that emerged exhibiteda bimodal profile that was the reverse of the parental popula-
tion. At early passage, the majority of cells were in the
p110ahigh state, and a minority was in the p110alow state,
with corresponding changes in pAKT (Figure 5A and Table
S2). These results suggest that only p110ahigh cells were
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Figure 4. PIK3CA Mutations Stabilize the p110ahigh State
(A) Asynchronously growing MCF10A cells stably expressing HA-tagged wild-type or mutant p110a (H1047R or E545K) were analyzed by flow cytometry.
Cells expressing the H1047R or E545K mutations had 2.0-fold and 1.7-fold, respectively, higher levels of p110a compared to wild-type.
(B) The proportion of cells within the p110ahigh/medium/low gates wasmeasured for the three cell lines. Bothmutant cell lines hadmore cells with high levels of
p110a and fewer cells with low levels of p110a.
(C) Asynchronously growing cells expressing wild-type p110a only havew25% of cells actively signaling or primed to activate signaling compared to >40%
in either mutant cell line. Numbers represent an average of three experiments.
(D) Cells expressingwild-type ormutant p110awere treated as described in Figure 2B. Total levels of p110a in thewhole population did not change over time
(solid lines), though the mutant cells retained higher average p110a levels than the wild-type cells. In the pAKThigh subpopulations (dashed lines), the
mutants followed similar dynamic changes in p110a levels as described for wild-type, though with much greater variability.
(E) Asynchronously growing wild-type andmutant lines were treatedwith CHX orMG132 as described in Figure 3A. All cell lines showed a decrease in p110a
levels following treatment with CHX. However, the mutant lines were less sensitive to the MG132 treatment than the wild-type line.
(F) Average AKT activity in asynchronously growing wild-type andmutant cell populations wasmeasured by flow cytometry. The H1047R and E545Kmutant
lines exhibited 3.9-fold and 2.4-fold increases, respectively, in total pAKT level compared to wild-type. Data are from at least three independent experi-
ments, and error bars represent standard error of the mean.
(G) Wild-type and mutant cells were analyzed by immunofluorescence, as described in Figure 1.
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178capable of forming colonies, at least partially by maintaining
high AKT activity. This is likely important for overcoming low
cell-density-related and replicative stresses, because we
observed that cell lines overexpressing p110a, either wild-
type or mutant, survived many more serial passages than
clones with only endogenous levels of p110a (Figure 5B and
Table S2).
If enrichment for p110ahigh cells is important in the early
stages of colony formation, we next wanted to test whether
the clones reverted back to the parental distribution once the
population established steady exponential growth. We
compared p110a levels at early and late passages and indeedsaw reversion to the parental distribution with the majority of
cells in the p110alow state in late passages (Figure 5C). We
carefully monitored the rate of reversion by measuring p110a
levels in sequential passages and observed a gradual
decrease in the percentage of cells with high p110a in nearly
all clones by passage 8 (Figure 5D). This suggests that
p110ahigh cells are critical for colony formation and early clonal
expansion, but heterogeneous populations of predominantly
p110alow cells facilitate exponential growth. To ensure that
there was no genetic component to these effects, we estab-
lished a second generation of clones from primary clonal
populations and observed the same trends (Table S2).
Figure 5. Cells with High Levels of p110a Are Important for Colony Formation
(A) On passage 3, clonal cell lines were starved, acutely stimulated with 5 nM EGF, and analyzed by flow cytometry. In each set of histograms, the top (blue)
measures p110a and the bottom measures pAKT S473 of p110alow (green) and p110ahigh (red) cells.
(B) Clones overexpressing wild-type or mutant p110a survived more passages than cells with only endogenous levels of p110a. Additionally, expression of
either mutant form of p110a increased clonal viability at early passages compared to expression of wild-type p110a.
(C) Clones at late passage (>10) were analyzed as described in (A) and invariably reverted to the parental bimodal distribution characterized by a large
p110alow subpopulation and a small p110ahigh subpopulation.
(D) To monitor the rate of reversion, we measured the percent of cells with high levels of p110a by flow cytometry for six serial passages. Mutant clones
(middle and bottom) achieved higher p110ahigh percentages and reverted more slowly than wild-type clones (top). Notably, many mutant clones
(HR-5,6,7 and EK-10,8,11,14) failed to revert and instead ceased proliferating at early passage.
(E) Clones that stopped growing stained positively for senescence-associated b-galactosidase activity compared to an exponentially growing control line.
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Figure 6. Establishing Cell-Cell Contacts Stabi-
lizes the p110alow State
(A) Cells achieve w1.5 doublings every 24 hr,
thereby increasing the number of cell-cell
contacts.
(B) Asynchronously growing cells were harvested
every 24 hr and analyzed by flow cytometry. As
cell density increases, average p110a (left) and
pAKT (right) levels in the population decrease.
Data shown are from one representative experi-
ment.
(C) Analyzed on the subpopulation level, the
decrease in p110a can be attributed specifically
to a decrease in the p110ahigh subpopulation
and an accumulation of the p110alow subpopula-
tion.
(D) To verify these results, we grew cells tow50%
confluency and assessed p110a levels by immu-
nofluorescence (left). Cells with few or no cell-cell
contacts (white circles) stained brightly for HA-
p110a, whereas cell clusters with many cell-cell
contacts (orange boxes) displayed heterogeneity
in HA-p110a staining intensity. The number of
cell-cell contacts was counted for 875 individual
cells and compared to their p110a status (right).
p110ahigh cells were enriched for cells with 0–1
cell-cell contacts, and p110alow cells were en-
riched for cells with 2–4 cell-cell contacts.
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kinetics after EGF stimulation to parental populations (Figures
S4A–S4C).
Interestingly, at passage 3, both H1047R- and E545K-
derived clones harbored higher percentages of p110ahigh cells
compared to wild-type clones and reverted to the parental
distribution at a slower rate than wild-type (Figure 5D). This
is consistent with our previous observation that mutant
p110a can stabilize the p110ahigh state (Figure 4; Figure S4D).Importantly, the few clones that failed to
undergo a reversion to the parental
distribution were predominantly mutant
clones with very high percentages of
p110ahigh cells (Figure 5D). These clones
ceased to proliferate after passage 3–4
and exhibited a spindly morphology
and senescence-associated b-galacto-
sidase activity (Figure 5E). We find these
data to be consistent with a model in
which reversion to a bimodal distribution
of primarily p110alow cells is required to
maintain exponential growth and in
which failure to revert results in onco-
gene-induced senescence.
Establishing Cell-Cell Contacts
Stabilizes the p110alow State
If low cell density contributed to the
induction of high p110a during colony
formation, we wanted to explore the
possibility that increasing cell-cell
contacts induces the p110alow state.
We measured p110a levels of exponen-
tially growing populations every 24 hr
and found that p110a and pAKT levels
steadily decreased as cell densityincreased (Figures 6A and 6B). The decrease in total p110a
can be attributed specifically to a drop in the proportion of
p110ahigh cells and an accumulation of p110alow cells (Fig-
ure 6C). This is also apparent in small cell clusters, where
p110a levels are heterogeneous compared to lone cells that
tend to be p110ahigh (Figure 6D). Under these low-density
growth conditions, the p110ahigh population is enriched for
cells with 0–1 cell-cell contacts, whereas the p110alow popula-
tion is enriched for cells with 2–4 cell-cell contacts (Figure 6D).
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establish contact inhibition and/or confluence arrest.
We next considered the possibility that cells with high AKT
activity are enriched at the unencumbered edges of tumors,
which are less confluence inhibited and highly proliferative.
These ‘‘pushing margins’’ are a distinct, though molecularly
uncharacterized, feature of mutant BRCA1-driven tumors
[25, 26]. We thus stained mammary tumors arising from
MMTV-Cre; BRCA1flox/flox; p53+/2 mice for pAKT S473. We
detected heterogeneous pAKT positivity throughout the tumor
(Figure S5A) and an enrichment of pAKT-positive cells along
pushing margins (Figures S5B–S5F) and in the lumens of
ductal hyperplasias (Figures S5G and S5H). Both of these
regions represent areas with fewer cell-cell contacts, support-
ing our hypothesis that low cell density enhances the pAKT-
positive state. However, given that no antibodies against
p110a or p85a are amenable to immunohistochemical stain-
ing, we cannot confirm that this high AKT activity correlates
with high PI3K protein.
Discussion
Nongenetic cell-to-cell variability has been observed in
numerous cellular systems and can lead to distinct cellular
fates. The most classic example is Ferrell and Machleder’s
study of Xenopus oocyte maturation, which shows that
variability in mitogen-activated protein kinase phosphoryla-
tion leads to either a G2 or metaphase arrest [27]. Similarly,
high or low levels of Nanog determine the potential of embry-
onic stem cells to terminally differentiate [10, 28], and high or
low levels of Sca-1 dictate the proclivity for hemapotoietic
progenitor cells to commit to the erythroid or the myeloid
lineage [29]. Another cellular fate that is determined by variable
protein expression is the drug-tolerant/drug-sensitive state. In
certain cell lines, gefitinib resistance can be conferred by high
IGF-1R signaling and high KDM5A expression [7], and campto-
thecin resistance can be conferred by high DDX5 or RFC1
expression [4]. Our study now shows that heterogeneity in
signal transduction is another meaningful source of cell-to-
cell variability that does not result in distinct cell fates, but
rather influences the transient behavior of the entire
population.
We show that a bimodal distribution of AKT activation is an
invariable characteristic of exponentially growing MCF10A
cells. We propose that limiting AKT activity to only 20%–30%
of cells in a population serves two related purposes: (1) to
prevent senescence, and (2) to maintain suboncogenic levels
of PI3K activity in large populations.
Our data show that clonal populations that are unable to
revert to the parental distribution of primarily p110alow cells
undergo cellular senescence. In these clones, p110ahigh;
pAKThigh cells comprise 80%–90% of the population immedi-
ately prior to senescence, indicating that such high PI3K
activity is not sustainable. These results are consistent with
models of p53-dependent cellular senescence associated
with the loss of two negative regulators of PI3K, PTEN and
inositol polyphosphate 4-phosphatase type II (INPP4B) [30,
31]. Given that MCF10A cells are p53 replete, it is possible
that overaccumulation of p110ahigh cells induces senescence
by the same mechanism.
A second selective advantage of maintaining variability in
PI3K activity may be to maintain suboncogenic levels of PI3K
activity in large populations such as tissues and organs. Given
that overactivation of this pathway is one of the most frequentevents in cancer, permitting PI3K activation in only a fraction of
cells within a population may be a simple mechanism to limit
overall PI3K activity. However, we show that variability is not
completely overcome in populations expressing oncogenic
forms of p110a or in epithelial tumor sections, which may
have important implications on tumor susceptibility to PI3K
inhibitors.
Assuming that only tumor cells with high levels of pathway
activation are likely to die in response to acute inhibition of
PI3K, then tumors with mosaic patterns of pathway activation
(e.g., as judged by pAKT staining) will exhibit only a partial
response to a PI3K (or AKT) inhibitor. The mosaic pattern of
pathway activation could be due to genetic variability or
oscillation between high and low levels of PI3K expression
(as seen in MCF10A cells). In the latter case, it may be possible
to kill a larger fraction of the tumor cells by adjusting the
therapy to ensure that the subset of cells that are protected
from PI3K inhibitor therapy at the time of the initial dose
become exposed to the inhibitor a second time as they cycle
into a high PI3K pathway state. Thus, a detailed understanding
of the pharmacokinetics of the drug is important in deciding
the intensity and frequency of dosing. Although continuous
high doses of PI3K inhibitors over several days or weeksmight
effectively kill all tumor cells as they cycle into the high activity
state, dose-limiting toxicities might preclude such treatment.
An alternative approach of using a very high single dose
once a week could avoid toxicities associated with continuous
dosing and result in 20%–30% tumor cell death at the first
treatment, followed by a period in which another 20%–30%
of the resistant tumor cells cycle into the high PI3K pathway
state and die at the second treatment and so on.
Various preclinical studies using PI3K inhibitors may
support this hypothesis. Once-daily oral administration of
the Novartis pan-PI3K/mTOR inhibitor, NVP-BEZ235, to
tumor-bearing mice results in delayed tumor growth but rarely
tumor regression. pAKT is ablated in these tumors 1–2 hr after
dosing but reemerges several hours later [32–34]. Similar
results were observed using the Genentech class 1A PI3K
inhibitor, GDC-0941 [35, 36]. Our data would suggest that cells
that were PI3Klow;pAKTlow during the initial dose escaped the
toxic effects of the drug and cycled to the PI3Khigh;pAKThigh
state several hours later when concentrations of the drug
decreased. The possibility that PI3K inhibitors are selectively
targeting the advancing edges or ‘‘pushingmargins’’ of tumors
is also consistent with fact that these tumors are not
advancing, but rather are stabilizing.
As we emphasized throughout this study, variability in PI3K
activity in cell populations is a regulated process. Though the
mechanism regulating PI3K degradation and resynthesis is
beyond the scope of this study, it is tempting to consider inhi-
bition of resynthesis to dampen PI3K activity in all cells.
Another alternative is to inhibit the E3 ligase that targets
PI3K for degradation, which may overactivate the pathway in
all cells and induce cellular senescence. This ‘‘prosenes-
cence’’ approach has recently shown promise in a prostate
cancer xenograft model where PTEN is pharmacologically in-
hibited [37].Experimental Procedures
Cell Lines and Cell Culture
MCF10A cells were obtained from the American TypeCulture Collection and
cultured as described by Debnath et al. [38]. Stable MCF10A cell lines ex-
pressing HA-tagged wild-type or mutant (H1047R or E545K) bovine p110a
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182were generated by retroviral infection as previously described [15]. Expres-
sion of wild-type and mutant PIK3CA cDNA was driven by the exogenous
CMV promoter of the JP1520 retroviral vector (J. Pearlberg). Where indi-
cated, cells were starved in growth media without horse serum, EGF, or
insulin for w20 hr. Acute stimulation with growth factors was done by
adding growth factor directly to the starvation medium.
Preparation of Cells for Flow Cytometry
A detailed description of how to prepare adherent cells for analysis by flow
cytometry is provided in the Supplemental Experimental Procedures.
Antibodies used for flow cytometry were: anti-HA.11-488 conjugate (Cova-
nce); anti-p-AKT S473 (D9E)-488/647 conjugates, anti-total AKT-647 conju-
gate, anti-pEGFRY1068 (Cell Signaling); anti-p85a (Upstate Biotechnology);
and various secondary Alexa Fluor dyes (Invitrogen). Data were analyzed
with BD FACSDiva software (BD Biosciences), FlowJo software (Tree
Star), and Cytobank [39].
Generation of Clonal Populations
Parental pooled populations were passaged >9 times in selection media to
normalize for infection efficiency. Parental cells were trypsinized, diluted,
and plated at a density of 1 cell/well. Colony formation was monitored daily,
and media were changed every 3 days. Once colonies grew to a sufficient
size, they were trypsinized and replated (passage 1), and serially passaged
thereafter.
Immunoassays
Detailed protocols for immunofluorescence, immunoblotting, and immuno-
histochemistry are provided in the Supplemental Experimental Procedures.
Supplemental Information
Supplemental Information includes five figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online
at doi:10.1016/j.cub.2010.12.047.
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